• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 9, 2014

View Archived Issues

Pharma: Other news to note

Wuxi Pharmatech Inc., of Shanghai, said its manufacturing subsidiary, Syn-The-All Pharmaceuticals Co. Ltd., started construction on a fully integrated R&D and cGMP manufacturing site in Changzhou, about 110 miles west of Shanghai. Read More

Clinic roundup

Aicuris AG, of Wuppertal, Germany, and Merck & Co. Inc., of Whitehouse Station, N.J., said phase II results were published in the New England Journal of Medicine showing the safety and efficacy of letermovir, an oral antiviral agent for the prevention of human cytomegalovirus (CMV) infection in patients receiving bone marrow transplant. Read More

Other news to note

Enanta Pharmaceueticals Inc., of Watertown, Mass., said partner Abbvie Inc., of Chicago, submitted a marketing authorization application for ABT-450 to the EMA seeking approval of the all-oral, interferon-free regimen for the treatment of adults infected with chronic genotype 1 hepatitis C virus. Read More

Stock movers

Read More

Earnings roundup

Dendreon Corp., of Seattle, reported total revenue of $68.8 million for the first quarter, just missing consensus estimates of $69.2 million. Read More

A-T, G-C . . . and more? Synthorx launched on new DNA base pair tech

Synthorx Inc., a new synthetic biology company backed by Avalon and Correlation Ventures, is leveraging exclusive rights to a technology for creating synthetic DNA base pairs to improve the discovery and development of new medicines, diagnostics and vaccines. Read More

Dystrophin is newly identified tumor suppressor

What does the loss of dystrophin lead to? Well, yeah, dystrophy. And, sometimes, metastatic cancer. Read More

Yakult Honsha, 4SC to tackle liver cancer in Japanese patients

apanese firm Yakult Honsha Co. Ltd. completed phase I trials for resminostat – licensed from German firm 4SC AG – in solid tumors, as the partners hope to move forward with the target indication of hepatocellular carcinoma (HCC) in Japan, where liver cancer is one of the largest causes of cancer-related death. Read More

India looking at noncommercial use for BMS' dasatinib

India is considering waiving a global patent for cancer drug dasatanib under provisions of the country's Patent Act that allow it to make the move for public noncommercial use. Read More

Panel advises working the system to get a CFDA greenlight

SUZHOU, China – Navigating the obstacle course of China's regulatory system requires strategic thinking, long-term planning, creative problem solving and it doesn't hurt to have deep pockets, according to the experts discussing cross-border approvals at the Chinabio Partnering conference. Read More

Local VCs boost prospects of China's life sciences sector

SUZHOU, China – Venture investing in China's life sciences industry continued a three-year upswing in 2013, according to speakers at the Chinabio Partnering Forum, with more than $1 billion in publicly disclosed deals last year. Read More

'Alder' lang syne: $80M low IPO another signal good times are over

As the initial public offering (IPO) flood slowed to a trickle, Alder Biopharmaceuticals Inc.'s $80 million deal did little to raise optimism, as the firm priced an upsized number of shares at a lower price to raise an amount far below the $115 million targeted in March, when the company filed to go public. The Bothell, Wash.-based firm hiked the number of shares from 7.2 million to 8 million, selling them at $10 each, under the projected $13-to-$15 range. (See BioWorld Today, March 20, 2014.) Read More

Pharma: Clinic roundup

Dompe Group, of Milan, reported preliminary phase I results confirming the tolerability of its recombinant human nerve growth factor (rhNGF), in development for ophthalmic use as a treatment for neurotrophic keratitis. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Ligachem inks two mystery ADC deals with CSPC subsidiary Novarock

    BioWorld
    Ligachem Biosciences Inc. signed two license agreements with Novarock Biotherapeutics Inc., a subsidiary of CSPC Pharmaceutical Group Ltd., to bring in two of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe